NRx Pharmaceuticals (NRXP) Scheduled to Post Earnings on Thursday

NRx Pharmaceuticals (NASDAQ:NRXP) is set to announce its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.06. On average, analysts expect NRx Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NRx Pharmaceuticals Trading Down 0.8 %

Shares of NRXP opened at $1.26 on Wednesday. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $7.33. The firm’s 50-day moving average price is $1.48 and its 200-day moving average price is $2.26. The firm has a market capitalization of $13.55 million, a price-to-earnings ratio of -0.47 and a beta of 1.27.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Ascendiant Capital Markets lifted their price objective on NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. HC Wainwright upped their price target on NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Finally, EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.